What Is The Fate And Effects Of Influenza Drug Tamiflu In Environment?

Tamiflu is being stockpiled all over the world for use in fighting the next influenza pandemic. However, there are growing signs that influenza viruses may develop resistance to this vital pharmaceutical, because it is routinely prescribed for seasonal influenza.

This research project is interdisciplinary and will combine studies on the environmental fate of the drug with in vivo studies of the development of Tamiflu resistant viruses say the project leader Björn Olsen at the Department of Medical Sciences Uppsala University.

This research project presents an innovative approach to studying the development of Tamiflu resistance in influenza viruses caused by environmental contamination which is a potential threat to one of our few defences against a future influenza pandemic.

Scientists from Uppsala University, Umeå University and Karolinska Institute will investigate the potential problem from an environmental chemical, virological and infectious diseases aspect.

A wide range of topics will be addressed; studies of the degradation of Tamiflu in sewage treatment plants will be combined with screening of the environmental levels in surface water in Japan. Japan is one of the world's top-per-capita consumers of Tamiflu and it has been estimated that approximately 40% of those that are infected by influenza viruses are treated with Tamiflu. This makes Japan one of the "Hot Spots" in the world and the research project has established collaboration with scientists at Kyoto University and several field sampling campaigns in Japan has been scheduled. Detected environmental levels will then be used in an in vivo Mallard infection model for detailed studies on the development of Tamiflu resistance in low pathogenic avian viruses. This will be combined with a screening study of the occurrence of resistant viruses in faecal samples from wild ducks in the vicinity of Japanese sewage treatment plants.

The full title of the project is "Occurrence and fate of the antiviral drug Oseltamivir in aquatic environments and the effect on resistance development in influenza A viruses." and the applicants are Björn Olsen, Dept. of Medicinal Sciences, Uppsala University, Åke Lundkvist, Dept. of Microbiology Tumour and Cellbiology, Karolinska Institute, Johan Lennerstrand, Dept. of Medicinal Sciences, Uppsala University and Hanna Söderström and Jerker Fick, Dept of Chemistry, Umeå University